GlassScriptPhysician profile
Julio C Cruz
NPI 1871588723
$10,457.12
in general payments reported to CMS, 2019-2025
35 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,934 · 2020: $317 · 2021: $983 · 2022: $1,152 · 2023: $1,615 · 2024: $1,655 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,968 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,968.22 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,369.75 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,133.34 | 2019-2025 | Tremfya |
| Genzyme Corporation | $757.52 | 2019-2025 | |
| Lilly USA, LLC | $701.34 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Dermavant Sciences, INC. | $680.66 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $630.61 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Ucb, INC. | $469.73 | 2019-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $450.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $333.85 | 2019-2025 | Libtayo, Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $332.01 | 2019-2024 | Arazlo, Cabtreo |
| Prugen, INC. Pharmaceuticals | $262.73 | 2019-2020 | |
| Pfizer INC. | $252.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $217.03 | 2019-2024 | |
| Amgen INC. | $192.02 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $186.36 | 2019-2025 | Ilumya, Blu-U, Odomzo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $184.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $154.03 | 2022-2025 | Sotyktu |
| Almirall LLC | $146.48 | 2019-2023 | Klisyri |
| Dermira, INC. | $139.03 | 2019-2021 | |
| Organon LLC | $122.13 | 2025 | Vtama, Nexplanon |
| Leo Pharma INC. | $112.91 | 2019-2023 | Adbry |
| Incyte Corporation | $111.65 | 2021-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $97.79 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $96.40 | 2019 | |
| Mayne Pharma Commercial LLC | $74.29 | 2019-2023 | |
| Botanix Sb INC | $43.98 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $33.88 | 2024-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $32.48 | 2023-2024 | Ycanth |
| Melinta Therapeutics, LLC | $29.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.02 | 2023 | Spevigo |
| Biofrontera INC. | $20.78 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Merck Sharp & Dohme LLC | $18.02 | 2019 | |
| Aclaris Therapeutics, INC. | $15.74 | 2019 | |
| Fresenius Kabi USA, LLC | $15.19 | 2023 | |
| Strata Skin Sciences, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.